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Aim: The purpose of this study was to examine the usefulness of using Simultaneous Inte-
grated Boost (SIB) radiotherapy for thyroid cancer treatment.
Background:At our hospital a 3DConformal RadioTherapy (3D-CRT) technique involving pho-
ton and electron beams for the treatment of thyroid cancer was often used.1 High dose to the
spinal canal was limiting the total dose of such a treatment. After investigation of Intensity
Modulated Radiotherapy (IMRT) technique involving seven photon beams for ﬁrst course of
treatment3 we decided to examine possibility of reducing treatment fractions by using SIB
radiotherapy.
Material and methods: Plans for 10 patients were studied. For each patient, IMRT plan for
the ﬁrst course of treatment (50Gy for PTV), two plans for the second course of treatment
(10Gy for BOOST) and a SIB plan (50Gy for PTV, 56Gy for BOOST) were prepared. For all
plans, comparisons of dose statistics for the PTV, BOOST, PTV without BOOST (deﬁned as
PTV without BOOST with 1 cm margin), spinal canal and Patient Outline (Body) was done.
Results: Minimum dose for BOOST is higher in the SIB technique than in the two course
treatment. PTV without BOOST receives the same average dose in SIB and the 1st course
IMRT – 50.10Gy and 49.84Gy, respectively. In the SIB technique, higher reduction of dosedelivered to the spinal canal is possible (27Gy compared with 30Gy).
Conclusion: SIB therapy for thyroid cancer with relation to typical two course treatment is a
good proposal of reducing the number of fractions with the same dose for BOOST and PTV
without BOOST. Additionally, better sparing of the spinal canal is achieved.
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. Introduction
he Maria Sklodowska-Curie Memorial Cancer Centre in War-
aw often used the 3D Conformal Radiotherapy (3D-CRT)
echnique, involving 4 and more photon and electron beams,
or treatment of thyroid cancer.1 High dose to the spinal canal
imited the total dose of such a treatment. After implementa-
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tion of the IMRT technique involving seven photon beams for
ﬁrst course of treatment3 we decided to examine the possi-
bility of reducing treatment fractions by using Simultaneous
Integrated Boost (SIB) radiotherapy. This approach was pre-
sented by Mohan et al. in 2000. SIB is the application of IMRT
(known also as simultaneous modulated accelerated radiation
therapy – SMART) in which high and low risk volumes are irra-
diated with different fraction dose in the same time. Normally,
. Published by Elsevier Urban & Partner Sp. z.o.o. All rights reserved.
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Fig. 1 – Dose distribution for 3D-CRT boost for one
representative patient included in the study. Isodoses are
the dose distribution in the PTV without BOOST was investi-
gated (see Figs. 3–6; Table 2), especially mean dose which can
behigherwith regard to dose gradient. The SIB technique gives
the same dose as in the 1st phase of IMRT treatment. When156 reports of practical oncology an
patients with head and neck cancers (especially with thyroid
cancer) are irradiated with 2Gy/fraction in the ﬁrst phase of
treatment and then high risk volume is irradiated to higher
total dose with the some dose per fraction (2Gy/fraction).
According to the linear quadratic model, it is assumed that
the same radiobiological effect (for tumor) can be achieved by
irradiating with higher dose per fraction and with less num-
ber of fractions. Some clinical comparisons for classic and SIB
irradiation have also been done.5–8
2. Material and methods
Plans for 10 patients irradiated with 3D-CRT were studied.
The PTV (at least 3mm under skin), BOOST, spinal canal and
patient outline were drawn on CT scans. For each patient, an
IMRT plan for the ﬁrst phase of treatment (50Gy for the PTV in
25 fractions) and two alternative plans, IMRT and 3D-CRT, for
the second phase of treatment (10Gy for BOOST in 5 fractions)
were prepared. The SIB plan (50Gy for PTV, 56Gy for BOOST
in 25 fractions) was compared with the technique consisting
of two phases. All IMRT and SIB plans were performed with
seven 6MV ﬁelds, the same beam geometry: 204◦, 256◦, 308◦,
0◦, 52◦, 104◦, 156◦ and 3◦ rotation of collimator.
In order to compare plans, dose statistics (minimum, max-
imum and mean dose, standard deviation) for the PTV, BOOST,
PTV without BOOST (deﬁned as the PTV without BOOST with
1 cm margin), spinal canal and Patient Outline (BODY) were
analyzed. For the SIB technique, dose statistics and Dose
Volume Histograms (DVH) for doses higher than 50Gy were
converted to 2Gy fraction. Parameter ˛/ˇ =2 was applied. The
TCI+C (Uncomplicated Target Conformity Index for Comparing
Plans) methodology for comparing DVH was used2,3,9,10 (see
Eq. (1)). A Normal Tissue Sparing Index for Comparing Plans,
NTSIC (used in TCI+C ), was calculated for test doses connected
with the test volumedeﬁnedas aminimumvolume receiving a
test dose in compared plans. NTSIC was scaled by a percentage
difference of DVH for normal tissues. In order to compare two
phase treatment versus SIB, the BOOST, PTV without BOOST
and spinal canal volume were considered. The BOOST, spinal
canal and whole patient body were used in comparison of
IMRT and 3D-CRT second phase of treatment.
TCI+C =
NT∏
i=1
TCIi
MNT∏
j=1
NTCICj (1)
where, TCI+C is the Uncomplicated Target Conformity Index
for Comparing Plans; TCI is the Target Conformity Index (cal-
culated for minimum and maximum doses equal to 95% and
107% of the prescribed dose respectively); NTSIC is the Nor-
mal Tissue Sparing Index for Comparing Plans (here scaled by
percentage difference of DVH between compared plans); NT is
the amount of target volumes; MNT is the amount of normal
tissues.3. Results
The plans were accepted with regard to the PTV/BOOST cov-
erage while 99% of target volume received at least 90% or 95%shown as thick lines, while PTV, BOOST, spinal canal and
patient outline are shown as thin lines.
of prescribed dose for the 3D-CRT and IMRT plans, respec-
tively. In all types of plans at most 1% of target volume (PTV
or BOOST) received dose higher than 107%. The comparison of
3D-CRT and IMRT as a 2nd phase of treatment was done ﬁrst.
TCI was better for the IMRT boost (average 1 compared to 0.88).
Higher conformity of the IMRT plan requires delivery of higher
doses for normal tissues. That is why, NTSIC for the body is on
average 0.98 for 3D-CRT and 0.86 for IMRT. Also for the spinal
canal, NTSIC is better for the 3D-CRT boost (on average 0.86 for
3D-CRT and 0.78 for IMRT). This result was caused by the use
of a smaller number of ﬁelds in the 3D-CRT technique, usually
outside the spinal canal. In fact, sparing of the spinal canal in
3D-CRT is mostly connected with underdosage in the BOOST
volume. TCI+C is 0.74 on average for 3D-CRT and 0.67 for IMRT
(see Figs. 1 and 2; Table 1).
While comparing SIB with a standard two phase treatment,Fig. 2 – Dose distribution for IMRT boost for one
representative patient included in the study. Isodoses are
shown as thick lines, while PTV, BOOST, spinal canal and
patient outline are shown as thin lines.
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Table 1 – Comparison of TCI, NTSIC and TCI+C for 3D-CRT and IMRT as the 2nd phase of treatment.
Patient no. TCI BOOST NTSIC SPINAL CANAL NTSIC BODY TCI+C
3D IMRT 3D IMRT 3D IMRT 3D IMRT
1 0.86 1.00 0.94 0.80 0.98 0.87 0.80 0.70
2 0.90 1.00 0.83 0.84 0.99 0.88 0.74 0.74
3 0.89 1.00 0.99 0.88 0.99 0.89 0.87 0.79
4 0.95 1.00 1.00 0.74 0.99 0.93 0.95 0.69
5 0.87 1.00 1.00 0.64 0.98 0.87 0.86 0.56
6 0.88 1.00 1.00 0.54 0.98 0.80 0.87 0.43
7 0.84 1.00 0.85 0.78 0.98 0.83 0.70 0.64
8 0.84 1.00 0.60 0.94 0.97 0.85 0.49 0.79
9 0.91 1.00 0.39 1.00 0.95 0.82 0.34 0.82
10 0.85 1.00 1.00 0.61 0.98 0.85 0.83 0.51
Average 0.88 1.00 0.86 0.78 0.98 0.86 0.74 0.67
Table 2 – Comparison of dose statistics for PTV without BOOST taking into account: minimum dose (min), maximum
dose (max), mean dose (mean), and dose standard deviation (std). Statistics for SIB were calculated by dividing absolute
dose by prescribed dose in ﬁrst phase of IMRT treatment.
Patient no. PTV without
BOOST min [%]
PTV without
BOOST max [%]
PTV without
BOOST mean [%]
PTV without
BOOST std [%]
mean
IMRT/SIB [1]
IMRT SIB IMRT SIB IMRT SIB IMRT SIB
1 89.1 84.1 106.3 110.1 99.4 99.6 2.0 2.2 1.00
2 83.2 83.9 106.6 107.6 99.7 100.4 2.0 2.1 0.99
3 90.0 92.2 106.1 110.3 99.9 100.6 1.4 1.8 0.99
4 92.9 92.6 104.9 107.1 100.4 101.7 1.5 2.0 0.99
5 89.6 91.8 106.4 105.9 98.7 98.2 1.6 1.6 1.01
6 88.5 91.8 106.4 108.5 100.0 100.2 2.1 2.2 1.00
7 86.4 86.4 105.7 107.5 99.7 99.9 1.9 2.1 1.00
8 84.4 90.3 105.8 110.8 99.8 100.4 2.1 2.4 0.99
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99 86.0 85.5 106.5 108.8
10 86.5 85.8 105.8 108.2
Average 89.0 88.9 106.1 108.2
he total dose to the PTV without BOOST was considered, it
as lower and more uniform in the SIB technique than in two
hase treatment. Dose statistics for the BOOST are presented
n Table 3. The minimum dose for the BOOST in two phase
herapy is 96–97% on average compared with 93% for 3D-CRT.
he maximum dose for the BOOST is almost the same. TCI
ig. 3 – DVH for PTV without BOOST volume for one
epresentative patient included in the study. 1st course
MRT (dotted) compared to SIB (solid). Vertical lines show
5% and 107% of prescribed dose (50Gy).99.9 100.9 1.8 2.2 0.99
99.2 100.1 1.5 1.7 0.99
99.6 100.1 1.7 1.9 1.0
for the BOOST equals 1 for two phase treatment and 0.99 for
the SIB technique. NTSIC for the spinal canal is better for SIB:
0.96 compared to 0.83–0.86 for two phase treatment. NTSIC for
the body is comparable for SIB and two phase treatment, and
because of that it does not have inﬂuence on the TCI+C parame-
ter (see Tables 4 and 5). The spinal canal receives higher doses
in two phase treatment – on average 30Gy compared to 27Gy
Fig. 4 – Dose distribution for IMRT+3D-CRT boost for one
representative patient included in the study. Isodoses are
shown as thick lines, while PTV, BOOST, spinal canal and
patient outline are shown as thin lines.
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Table 3 – Comparison of dose statistics for BOOST taking into account: minimum dose (min), maximum dose (max),
mean dose (mean), and dose standard deviation (std). Statistics for SIB were calculated by dividing absolute dose by
prescribed dose in two phases of treatment.
Patient no. BOOST min [%] BOOST max [%]
IMRT+3D IMRT+ IMRT SIB IMRT+3D IMRT+ IMRT SIB
1 95.4 97.2 93.0 105.3 106.1 104.7
2 96.6 97.2 94.2 104.7 105.3 103.9
3 96.6 96.8 93.9 105.4 106.1 105.9
4 95.5 95.0 93.6 101.3 101.4 101.6
5 96.5 97.3 91.7 104.9 105.5 104.3
6 93.9 94.2 91.8 103.8 103.9 104.0
7 89.8 90.9 88.3 105.2 105.2 104.6
8 96.3 96.1 92.4 105.0 106.2 104.2
9 88.0 88.5 86.9 104.6 105.6 106.0
10 93.6 94.4 91.7 106.3 107.8 104.3
Average 96.1 96.7 93.3 104.3 104.9 104.0
Patient no. BOOST mean [%] BOOST std [%]
IMRT+3D IMRT+ IMRT SIB IMRT+3D IMRT+ IMRT SIB
1 100.9 100.9 99.6 1.6 1.8 1.8
2 101.0 101.0 99.6 1.3 1.2 1.5
3 100.5 100.5 99.6 1.5 1.6 1.5
4 99.4 99.4 99.6 0.7 0.7 1.3
5 101.0 101.0 99.6 1.4 1.6 1.8
6 100.3 100.3 99.6 1.6 1.5 1.6
7 100.8 100.8 99.6 1.7 1.4 1.7
8 100.9 100.9 99.6 1.6 1.5 1.6
9 100.1 100.1 99.6 1.6 1.6 1.8
10 101.0 101.0 99.8 1.8 1.9 1.8
Average 100.5 100.6 99.6 1.3 1.4 1.6
Table 4 – Comparison of TCI, NTSIC and TCI+C for IMRT+3D and SIB.
Patient no. TCI BOOST NTSIC SPINAL CANAL TCI+C
IMRT+3D SIB IMRT+3D SIB IMRT+3D SIB
1 1.00 0.99 0.79 0.99 0.79 0.99
2 1.00 1.00 0.87 1.00 0.87 1.00
3 1.00 1.00 0.83 0.87 0.83 0.86
4 1.00 1.00 0.86 1.00 0.86 1.00
5 1.00 0.99 0.83 1.00 0.83 0.99
6 1.00 0.96 0.87 0.86 0.87 0.83
7 1.00 0.99 0.85 1.00 0.85 0.99
8 1.00 0.99 0.77 0.90 0.77 0.89
9 0.99 0.96 0.76 1.00 0.76 0.96
10 1.00 1.00 0.87 0.98 0.87 0.97
Average 1.00 0.99 0.83 0.96 0.83 0.95
Table 5 – Comparison of TCI, NTSIC and TCI+C for IMRT+ IMRT and SIB.
Patient no. TCI BOOST NTSIC SPINAL CANAL TCI+C
IMRT+IMRT SIB IMRT+IMRT SIB IMRT+IMRT SIB
1 1.00 0.99 1.00 1.00 1.00 0.99
2 1.00 1.00 0.87 0.98 0.87 0.98
3 1.00 1.00 0.82 0.87 0.82 0.86
4 1.00 1.00 0.83 1.00 0.83 1.00
5 1.00 0.99 0.81 1.00 0.81 0.99
6 1.00 0.96 0.86 0.86 0.86 0.83
7 1.00 0.99 0.86 1.00 0.86 0.99
8 1.00 0.99 0.85 0.90 0.85 0.89
9 0.99 0.96 0.85 1.00 0.84 0.96
10 1.00 1.00 0.83 1.00 0.83 1.00
Average 1.00 0.99 0.86 0.96 0.85 0.95
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Table 6 – Comparison of maximum dose for spinal canal.
Patient no. Max dose for spinal canal [Gy]
IMRT+3D IMRT+ IMRT SIB
1 32.91 33.25 29.09
2 33.18 31.29 31.26
3 26.58 26.98 26.60
4 28.80 29.86 25.11
5 38.62 39.50 29.01
6 28.44 30.26 28.75
7 28.21 26.98 24.60
8 28.80 28.25 26.73
9 31.97 30.36 27.17
10 24.85 27.14 25.37
Average 30.42 30.39 27.37
Fig. 5 – Dose distribution for IMRT+ IMRT boost for one
representative patient included in the study. Isodoses are
shown as thick lines, while PTV, BOOST, spinal canal and
patient outline are shown as thin lines.
Fig. 6 – Dose distribution for SIB for one representative
patient included in the study. Isodoses are shown as thick
lines, while PTV, BOOST, spinal canal and patient outline
are shown as thin lines.
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in SIB (see Table 6). But the dose for spinal canal in both tech-
niques is still far below the tolerance dose.
4. Discussion
IMRT is known as a technique with higher dose conformity
for thyroid cancer patients and better sparing of the spinal
cord.3,11 The SIB technique gives a chance of comparable con-
formity with better sparing of organ at risk. It is also less
time consuming than two phase treatment – both for plan-
ning (preparation of only one plan is needed) and treatment
(smaller number of fractions). In the SIB technique, the BOOST
has insigniﬁcantly lower minimum dose and TCI. The spinal
canal has 3Gy lower maximum dose than in two phase treat-
ment. In fact, for some plans maximum spinal canal dose
was almost the same. Dogan et al.7 reported no reduction
of spinal cord dose with SIB–IMRT compared to sequential
(two phases) IMRT. The same effect was observed by Fogliata
et al.6
Comparing dose in the whole body is rather difﬁcult
because of unknown radiobiological effect of different frac-
tionation doses in normal tissues. Dogan et al.7 received up to
70% lower volume of nontarget tissues receiving doses higher
than 15Gy for SIB–IMRT. In our study dose distributions seem
to be comparable for whole body irradiation. The same effect
is observed while we consider the volume of nontarget tis-
sues receiving doses >15Gy (mean difference was below 1%).
The PTV without BOOST volume in SIB therapy has almost the
same dose distribution as for the ﬁrst course of IMRT treat-
ment. That means that in the SIB technique, the PTV without
BOOST would not receive, from 2nd course of therapy, unnec-
essary dose leading to the raising of mean dose.
5. Conclusion
SIB therapy for thyroid cancer allowed us to accomplish our
goals: a reduction of the number of fractions with the same
BOOST and PTV without BOOST dose and better sparing of the
spinal canal. The PTV without BOOST volume does not receive
additional dose as in the case of the 2nd course in the non-SIB
technique. Before implementing the SIB technique for thyroid
cancer therapy, further discussion of total and fraction dose
should be carried out. It is possible that from clinical point of
view applying a higher prescribed dose may be beneﬁcial.
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